Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

PDF file - 70KB, Supplementary Table 2. Grade 3/4 Adverse Events that Occurred in ≥2% of Patients.